COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD) (STAIRWAY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03038880
Recruitment Status : Completed
First Posted : February 1, 2017
Last Update Posted : January 14, 2020
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 11, 2018
Actual Study Completion Date : March 29, 2018
Certification/Extension First Submitted : January 11, 2019